Drugs and other chemicals that have the potential to induce or exacerbate systemic autoimmune diseases in humans are of great concern. The aim of this study was to examine the immune-disregulating potential of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) by using the popliteal lymph node (PLN) assay. Chlorpromazine (CPZ) was used as a reference compound for 2 reasons: (a) CPZ is known to elicit a positive response in this assay, and (b) CPZ is a structural analogue of TCDD. Male Sprague-Dawley rats were injected subcutaneously with either TCDD or CPZ into the right hind footpad, whereas vehicle alone was injected into the contralateral footpad. Control rats were injected with vehicle in both hind footpads. Animals were sacrificed on day 7, and their PLNs were removed, weighed, and immersed in 10% formalin. The PLN weight index (the weight ratio of right PLN over left PLN) was significantly higher in both CPZand TCDD-treated rats than in controls. Histological examinations of PLNs in the CPZ-and TCDD-treated rats revealed similar morphological changes in both groups (e.g., mild follicular hyperplasia with no evidence of an acute inflammatory response). These results indicate that TCDD has the potential to induce or exacerbate autoimmunelike reactions. Results also suggest that drugs may be useful surrogates to study the mechanism of toxicity of environmental chemicals that cannot be administered to humans.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is an environmental chemical that is produced mainly from waste combustion, especially from medical and municipal sources. Exposure to TCDD produces a spectrum of effects (14, 15) . Of growing concern is the effect on the immune system. Research in this area has mainly focused on humoral immunity, cellmediated immunity, and host resistance (9) . The potential of TCDD to induce autoimmune-like effects has not been well studied, although antinuclear antibodies and immune complexes were detected significantly more frequently in the peripheral blood of workers exposed to dioxins than in unexposed individuals (10) . The aim of this study was to in-vestigate immunomodulating effects ofTCDD using the popliteal lymph node (PLN) assay, which has been proposed as a tool to predict autoimmune-like reactions induced by chemicals (2) . For environmental chemicals, it is usually not possible to correlate results from animal studies to human data because availability of the latter is almost always very limited. In contrast, a large amount of clinical/toxicological information is available for pharmaceutical drugs. Thus, studying environmental chemicals in comparison with structurally similar drugs is a potential tool for improving risk assessments for humans. Chlorpromazine (CPZ) was at one time a widely used antipsychotic drug. It has a 3-ring structure similar to TCDD and has been reported to have a potential to induce or exacerbate systemic autoimmune diseases such as systemic lupus erythematosus in humans (3) . Furthermore, this drug has tested positive by the PLN assay in both mice and rats (12, 16) . This experiment was de- signed to examine the immunomodulating effects of TCDD using the PLN assay and compare the results and pathological changes to those of CPZ, its structural analogue.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats (Charles River, Boston, MA) were housed individually in stainless-steel, wire-bottom cages and allowed free access to feed (Purina 5001, Ralston Purina, St. Louis, MO) and polished water during a 1-wk adaptation period. Body weight of the rats on the day of experiment was 200-250 g, with an approximate age of 7-8 wk.
Materials. CPZ (Sigma, St. Louis, MO) was dissolved in dimethylsulfoxide (DMSO, Sigma) at 100 mg/ml and injected at 5 mg/50 ~1 as previously done by others (2, 16) . TCDD (purity > 99%, Cambridge Isotope Laboratories, Woburn, MA) was dissolved in DMSO at 32.2 ~g/ml and injected at a dose of 10 Ag TCDD/kg, which is a sublethal dose in rats. This dose, however, was shown to affect the immune system previously (4) . PLN Assay. The PLN assay was performed as described by Descotes (2) . On day 0, groups of 6-10 rats were injected subcutaneously with 50 41 of TCDD or CPZ into the right hind footpad, whereas vehicle (DMSO) alone was injected into the contralateral footpad. Control rats were injected with vehicle in both hind footpads. Animals were sacrificed on day 7, and their PLNs were carefully removed, cleaned, and weighed.
Histological Examination. Immediately after weighing, PLNs were preserved in buffered neutral formalin. Tissues were embedded with paraffin, sectioned at 5 ~.m, and stained with either hematoxylin and eosin or methyl green pyronine (plasma cell stain). Histologic sections were examined blind (by D.M.P.) without knowledge of the experimental groups. Follicle and germinal center development, cellularity of T cell-dependent areas, and inflammatory responses were evaluated by scoring lesions from 1 to 5, with 1 representing minimal and 5 extensive changes. Statistical Analysis. Analysis of significance was performed using Student's t-test with p < 0.05 considered as statistically significant.
RESULTS

PLN Index
Data were expressed as PLN index, which is the weight ratio of PLN of the injected, ipsilateral over the noninjected, contralateral paw. Means of individual PLN indices ± SEM were calculated for the treated and control groups and are shown in Fig. 1 .
PLN index was 2.58 ± 0.5 in CPZ-treated rats and 1.59 ± 0.2 in TCDD-treated rats, both significantly higher (p < 0.05) than those of control rats (1.07 ± 0.2).
Morphology
Control Rats ( Fig. 2A, B ). Three of 4 animals injected with vehicle had minimal follicle and rare germinal center development ( Fig. 2A, B) . One animal had numerous follicles in the right but only rudimentary follicles in the left node. Cellularity of the interfollicular cortex varied from animal to animal. Acute inflammatory changes were not a feature of any of the nodes, although most developed some degree of sinus histiocytosis and variable degrees of mast cell infiltration. Differences in plasma cell populations were not detectable.
CPZ-Treated Rats (Fig. 2C, D ). Mild differences in follicle and germinal center development were noted between the nodes from the test (right) and control (left) feet in 2 of 4 animals treated with CPZ (Fig. 2C, D) . In those 2 animals, follicle and germinal center developments were greater in the treated feet. Treatment with CPZ was not associated with histologically detectable differences in interfollicular cellularity. Sinus histiocytosis and macrophage infiltration were present in several test and control nodes. Acute inflammatory changes were not a feature of CPZ treatment. Differences in plasma cell populations were also not detectable.
TCDD-Treated Rats (Fig. 2E, F) . Five of 6 animals showed minimal to mild histologically detectable differences in follicular development be- (A and B) , CPZ (C and D), or TCDD (E and F). A, C, and E are lymph nodes from the left foot (control), and B, D, and F are lymph nodes from the right foot (treated). Follicular development is apparent in nodes from the CPZand TCDD-treated feet compared to those from control feet, whereas no follicular development is apparent in control animals. x45. tween the test (right) and control (left) nodes (Fig.  2E, F) . Only 1 animal had minimal germinal center development in the test node without any development in the control node. Differences in interfollicular cellularity between the test and control nodes were not consistent from animal to animal.
Sinus histiocytosis was variable, and acute inflammatory changes were not a feature of any of the nodes. Differences in plasma cell populations were also not detectable.
DISCUSSION
Autoimmunity associated with drugs and other chemicals in humans is of growing concern. The PLN assay was originally developed for quantitation of graft versus host (GvH) activity of lymphocytes (5) and later introduced for the study of chemicalinduced autoimmunity because of the mechanistic similarity between the 2 responses (6, 8) . In GvH reactions, donor T cells activated by allogeneic major histocompatibility (MHC) class II molecules provide help for autoantigen-recognizing B cells to produce autoantibodies. Similarly, activation of autologous T cells by chemical-modified self-antigens can cause autoantibody formation by providing nonspecific help to autoantigen-recognizing B cells (7) . Results obtained using the PLN assay with more than 70 compounds in either mice (12) or rats (16) showed a good correlation with clinical data in that drugs with autoimmune case reports in humans (&dquo;positive reference compounds&dquo;) had significantly higher PLN weight indices in this assay, and vice versa. Therefore, the PLN assay is considered to be a reliable tool to predict those chemicals likely to induce autoimmune-like reactions in humans (2) . Unlike drugs, environmental chemicals such as TCDD cannot be administered to humans for experimental purposes. Because the number of occupationally or accidentally exposed humans is dwindling, a direct validation of animal data in humans will become impossible. The only remaining option will be to use structurally similar drugs as surrogates to establish the validity of animal models for humans by proving identical mechanism(s) of action. CPZ was selected as a positive reference compound under these considerations because it was reported to induce autoimmune reactivity in humans (3) and because it also tested positive by the PLN assay in rats ( 16) . Figure 1 shows that PLN weight index, the standard endpoint in the PLN assay, was significantly elevated in CPZ-treated rats, which represents confirmation of results obtained by another laboratory (16) . It was also significantly increased in TCDD-treated rats, which has not been reported before. Because false-positive results were found among primary irritants (11) , routine histology of PLNs was suggested as a means to identify and discard primary irritants ( 1 ) . As described in the Results section, similar histological changes were seen in PLNs of CPZ-and TCDD-treated rats without evidence of inflammatory changes, which excludes the possibility of a false-positive result. It is necessary to point out that in a recent paper Korte et al. (13) reported no immunosuppressive effect of TCDD in the PLN assay in rats. The protocol of the PLN assay used by that group was different from the one used in this study. The former was described as an &dquo;adoptive transfer PLN assay,&dquo; in contrast to the present &dquo;direct PLN assay&dquo; (13) . The former assay was developed to detect immunosuppressive effect of chemicals, whereas the one used by us to identify autoimmune-like effects.
The mechanism of how TCDD interferes with MHC class II molecules on antigen-presenting cells (macrophages) and thus activate CD4+ helper T cells to result in this GvH-like autoimmune reaction is not clear. The results of this study are in agreement with previous findings from our laboratory that TCDD at low doses enhances delayed-type-hypersensitivity reaction in rats (4) . In both instances, macrophages and/or T-helper cells are activated by TCDD treatment.
In conclusion, TCDD has tested positive by the PLN assay in this experiment, which could have implications for human risk assessment. This study also suggests that studying environmental chemicals using structurally similar drugs as surrogates will aid toxicologists in investigating mechanisms of action of toxicants in humans indirectly.
